The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Myelodysplastic Syndromes
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
-
Community Cancer Institute, Clovis, California, United States, 93611
John Muir Medical Center - Concord Campus, Concord, California, United States, 94520
Compassionate Cancer Care Medical Group, Fountain Valley, California, United States, 92708
Local Institution - 0095, Fresno, California, United States, 93703
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States, 90720
Local Institution - 0258, Los Angeles, California, United States, 90095
Local Institution - 0247, Orange, California, United States, 92868
Ventura County Hematology Oncology Specialists, Oxnard, California, United States, 93030
Local Institution - 0098, Fort Collins, Colorado, United States, 80528
Hartford Hospital (HH), Hartford, Connecticut, United States, 06102
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2030-03-11